Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Chief Business Officer | March 02, 2023 | March 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,162 |
Reported balance
After 2023-03-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-03-02 · Grant · Acquired 107,202 · Balance 259,162 F1: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 107,202 newly awarded RSUs, 62,448 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 89,512 shares of common stock. On March 2, 2023, 20,816 of Prior RSUs vested and 41,632 of Prior RSUs remained unvested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 107,202 newly awarded RSUs, 62,448 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 89,512 shares of common stock. On March 2, 2023, 20,816 of Prior RSUs vested and 41,632 of Prior RSUs remained unvested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2023 Filed Mar 6, 2023 21:28 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 107,202 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-006529 · wf-form4_167813811794255.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,162 F1 · shares: Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · balance_after: The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 107,202 newly awarded RSUs, 62,448 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 89,512 shares of common stock. On March 2, 2023, 20,816 of Prior RSUs vested and 41,632 of Prior RSUs remained unvested. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 21:05 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Stock | 30,000 | $5.16 | $154,800.00 |
DisclosureSEC source: 0001628280-22-029215 · wf-form4_166802789941411.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,512 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.98 to $5.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantStock Option (right to buy) · Derivative | 106,838 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · derivative · entry 4 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,838 Underlying: Common Stock · 106,838 shares Expires 2032-03-02 F4 · derivative.exercise_date: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantRestricted Stock Unit · Derivative | 62,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · derivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,448 Underlying: Common Shares · 62,448 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. F3 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 4,849 | $12.01 | $58,236.49 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,512 F2 · shares: Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 21:13 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-005130 · wf-form4_164642837303389.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,361 F1 · shares: On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 29,000 | $0.00 Strike: $18.38 | $0.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · derivative · entry 7 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,900 Underlying: Common Stock · 29,000 shares Expires 2030-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F7 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 11,000 | $29.50 | $324,500.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 6 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 29,000 | $28.82 | $835,780.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 5 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.60 to $29.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 21:18 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 29,000 | $18.38 | $533,020.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 4 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:18 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 10,000 | $30.55 | $305,500.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.30 to $30.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:18 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 50,000 | $31.26 | $1,563,000.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.00 to $31.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:18 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 50,000 | $30.17 | $1,508,500.00 |
DisclosureSEC source: 0001628280-21-023169 · wf-form4_163675187710828.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:20 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001628280-21-021477 · wf-form4_163597080368439.xml · derivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2027-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:20 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 45,000 | $31.64 | $1,423,800.00 |
DisclosureSEC source: 0001628280-21-021477 · wf-form4_163597080368439.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,861 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.50 to $31.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 20:20 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 45,000 | $3.20 | $144,000.00 |
DisclosureSEC source: 0001628280-21-021477 · wf-form4_163597080368439.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 10,000 | $0.00 Strike: $18.38 | $0.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · derivative · entry 11 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,900 Underlying: Common Stock · 10,000 shares Expires 2030-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F7 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 70,000 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · derivative · entry 10 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2029-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F8 · derivative.exercise_date: The shares subject to the option vest in twenty-four equal monthly installments from the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 7,500 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · derivative · entry 9 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F7 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 87,500 | $24.02 | $2,101,750.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · nonDerivative · entry 7 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,861 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.90 to $24.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 10,000 | $18.38 | $183,800.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · nonDerivative · entry 6 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 70,000 | $6.06 | $424,200.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · nonDerivative · entry 5 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 21, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 7,500 | $5.30 | $39,750.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · nonDerivative · entry 4 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 28,500 | $5.30 Strike: $5.30 | $151,050.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · derivative · entry 8 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 28,500 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F7 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 16,000 | $21.60 | $345,600.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · nonDerivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,861 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce settlement agreement. F5 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.56 to $21.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 12,500 | $21.71 | $271,375.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,861 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.70 to $21.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 20:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 28,500 | $5.30 | $151,050.00 |
DisclosureSEC source: 0001628280-21-019048 · wf-form4_163234265014624.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 45,000 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · derivative · entry 8 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F8 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 45,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · derivative · entry 7 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F7 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 90,000 | $21.19 | $1,907,217.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · nonDerivative · entry 5 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,861 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce settlement agreement. F5 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $21.00 to $21.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 45,000 | $3.20 | $144,000.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · nonDerivative · entry 4 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 14, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 45,000 | $5.30 | $238,500.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · nonDerivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:01 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 44,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-018782 · wf-form4_163182609831779.xml · derivative · entry 4 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 44,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F6 · derivative.exercise_date: The shares subject to the option vest in thirty-six equal monthly installments from the grant date. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:01 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 30,000 | $21.80 | $654,000.00 |
DisclosureSEC source: 0001628280-21-018782 · wf-form4_163182609831779.xml · nonDerivative · entry 3 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,861 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.75 to $21.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:01 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 14,000 | $21.73 | $304,220.00 |
DisclosureSEC source: 0001628280-21-018782 · wf-form4_163182609831779.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,861 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in connection with a divorce agreement. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $21.71 to $21.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:01 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 44,000 | $5.30 | $233,200.00 |
DisclosureSEC source: 0001628280-21-018782 · wf-form4_163182609831779.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · derivative · entry 6 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 25,000 shares Expires 2028-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F6 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Shares | 25,000 | $5.30 | $132,500.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 22:16 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Shares | 25,000 | $19.80 | $495,000.00 |
DisclosureSEC source: 0001628280-21-018603 · wf-form4_163165777007172.xml · nonDerivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,861 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $19.76 to $19.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 07, 2021 Filed Sep 8, 2021 20:04 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 7,500 | $18.10 | $135,750.00 |
DisclosureSEC source: 0001628280-21-018219 · wf-form4_163113146158608.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2021. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:09 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 22,500 | $17.81 | $400,725.00 |
DisclosureSEC source: 0001628280-21-017720 · wf-form4_163009494191302.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,361 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2021. F2 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $17.76 to $17.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 20:09 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,000 | $16.01 | $80,050.00 |
DisclosureSEC source: 0001628280-21-016403 · wf-form4_162862613567685.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2021. F2 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| July 28, 2021 Filed Jul 29, 2021 20:09 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,000 | $13.86 | $69,300.00 |
DisclosureSEC source: 0001628280-21-014882 · wf-form4_162758934279152.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2021. F2 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the sold date. F3 · price: The price in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 20:06 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | SaleCommon Stock | 5,000 | $13.76 | $68,800.00 |
DisclosureSEC source: 0001628280-21-012730 · wf-form4_162447875291749.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,861 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2021. F2 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the sold date. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:30 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionOption Grant (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001628280-21-010021 · wf-form4_162085139436066.xml · derivative · entry 2 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. The expiration date was extended as a result of the blackout period. Read SEC document |
| May 11, 2021 Filed May 12, 2021 20:30 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | Exercise / conversionCommon Stock | 20,000 | $3.02 | $60,400.00 |
DisclosureSEC source: 0001628280-21-010021 · wf-form4_162085139436066.xml · nonDerivative · entry 1 Martin Michael Robert · CIK 0001837647 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.